Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | PLAT | P00750 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959652 | 1.00 | GRM5 (1.00) | GRM5KCNH2MAPTPLATTP53 | |
| SCHEMBL2959089 | 0.87 | GRM5 (1.00) | GRM5KCNH2MAPTPLATTP53 | |
| SCHEMBL2959324 | 0.84 | GRM5 (1.00) | GRM5KCNH2MAPTTP53NPC1 | |
| SCHEMBL2962057 | 0.84 | GRM5 (1.00) | GRM5KCNH2MAPTTP53NPC1 | |
| SCHEMBL1545804 | 0.83 | KCNH2 (0.83) | GRM5KCNH2MAPTTP53NPC1 | |
| SCHEMBL1544513 | 0.83 | KCNH2 (1.00) | GRM5KCNH2MAPTTP53NPC1 | |
| SCHEMBL1543911 | 0.83 | KCNH2 (1.00) | GRM5KCNH2MAPTTP53NPC1 | |
| SCHEMBL1543885 | 0.83 | KCNH2 (1.00) | GRM5KCNH2MAPTTP53NPC1 | |
| SCHEMBL2958368 | 0.83 | GRM5 (1.00) | GRM5KCNH2MAPTTP53NPC1 | |
| SCHEMBL14341519 | 0.82 | KCNH2 (0.81) | GRM5KCNH2MAPTTP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772235-B2 | mGluR5 modulators | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | GLRA1, GRM1, GRM5 | GRM5 3/4885KCNH2 576/4885MAPT 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.